Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi‐institutional retrospective analysis in 52 patients | Zendy

Valle M. | Zendy; Van der Speeten K. | Zendy; Garofalo A. | Zendy

Premium

Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi‐institutional retrospective analysis in 52 patients

Author(s) -

Valle M.,

Van der Speeten K.,

Garofalo A.

Publication year - 2009

Publication title -

journal of surgical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.201

H-Index - 111

eISSN - 1096-9098

pISSN - 0022-4790

DOI - 10.1002/jso.21321

Subject(s) - medicine , ascites , hyperthermic intraperitoneal chemotherapy , chemotherapy , refractory (planetary science) , intraperitoneal chemotherapy , surgery , laparoscopy , cancer , general surgery , cytoreductive surgery , ovarian cancer , physics , astrobiology

Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment‐related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites. J. Surg. Oncol. 2009;100:331–334. © 2009 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research